Pancreatic ductal adenocarcinoma (PDAC) is a lethal malignancy, with a five-year survival rate near 10%. The rarity of PDAC contrasts the abundance of its primary precursor lesion, pancreatic intraepithelial neoplasia (PanIN). PanIN is known to be common in surgically resected pancreas and to exist even in normal don...
Valentina Matos-Romero, Kara A. Lombardo, Daniela Higuera-Garrido et al.· Cancer Research· 0 citations
Pancreatic ductal adenocarcinoma (PDAC) is frequently diagnosed at advanced, metastatic stages, emphasizing the need to study the earliest events in disease progression. The tumor suppressor p53 strongly opposes PDAC development and is mutated in nearly 75% of cases, yet how wild-type p53 functions to delay cancer on...
Jessica L. Mann, Kathryn J. Hanson, Lucie Dequiedt et al.· Cancer Research· 0 citations
Pancreatic ductal adenocarcinoma (PDAC) emerges from precursor lesions (PanINs and IPMNs) that harbor mutations in the KRAS oncogene. Once thought to be untargetable, the KRAS oncoprotein can now be inhibited with small molecule compounds that bind to either the active or inactive form of the protein. KRAS inhibitors...
Ben Z. Stanger, Minh T. Than, Lucie Dequiedt et al.· Cancer Research· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.